Kazia Therapeutics Ltd ADR (KZIA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $10.57 (-2.67%), Market cap $0.15B, 52-week low–high $3.45 ~ $15.72.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It als
Financial statements, price targets, institutional (13F) holdings and related news for Kazia Therapeutics Ltd ADR are updated in real time on BlackAll Trade.
Kazia Therapeutics Ltd ADR trades at $10.57 (-2.67%). Real-time quotes and charts are available on BlackAll Trade.
Kazia Therapeutics Ltd ADR has a market cap of about $0.15B.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, br